[Clinical importance of morphological multilineage dysplasia in acute myeloid leukemia with myelodysplasia related changes].

BACKGROUND AML with myelodysplasia related changes (AML MRC) is known to show a poor prognosis compared with de novo AML, but controversies exist about the prognostic impact of multilineage dysplasia (MLD) among MRC. We investigated the prognostic impact of MLD in AML MRC. METHODS A total of 357 patients newly diagnosed as AML at Asan Medical Center from January 2001 to December 2005 were analyzed. They were diagnosed and classified as AML with recurrent genetic abnormalities, AML MRC, and AML not otherwise specified (AML NOS). Prognostic markers including overall survival (OS) and event free survival (EFS) were obtained through retrospective analysis of electronic medical records. RESULTS AML MRC patients showed a lower complete remission (CR) rate (44.7% vs. 64.9%, P=0.002) and shorter OS (297 vs. 561 days, P=0.004) and EFS (229 vs. 374 days, P=0.004) than AML NOS patients. Patients with MLD among AML MRC also showed a lower CR rate (37.7%, P=0.001) and shorter OS (351 days, P=0.036) and EFS (242 days, P=0.076) than AML NOS patients. However, among AML MRC patients, there were no differences in OS, EFS and CR between patients with and without MLD. CONCLUSIONS AML MRC patients showed a lower CR rate and shorter OS and EFS than AML NOS patients. AML MRC patients with MLD showed similar results and their prognosis was not different from those without MLD. MLD findings among AML MRC could be an independent poor prognostic factor in de novo AML.

[1]  J. Merker,et al.  Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. , 2008, Blood.

[2]  G. Ehninger,et al.  MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients. , 2008, Blood.

[3]  T. Naoe,et al.  Diagnosis of acute myeloid leukemia according to the WHO classification in the Japan Adult Leukemia Study Group AML-97 protocol , 2008, International journal of hematology.

[4]  R. Irons,et al.  Prospective study of 174 de novo acute myelogenous leukemias according to the WHO classification: subtypes, cytogenetic features and FLT3 mutations , 2006, European journal of haematology.

[5]  T. Naoe,et al.  Long‐term outcomes for unselected patients with acute myeloid leukemia categorized according to the World Health Organization classification: a single‐center experience , 2005, European journal of haematology.

[6]  M. Slovak,et al.  Prognostic Impact of Acute Myeloid Leukemia Classification , 2003 .

[7]  M. Slovak,et al.  Prognostic impact of acute myeloid leukemia classification. Importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival. , 2003, American journal of clinical pathology.

[8]  W. Hiddemann,et al.  Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Hossfeld.  E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues , 2002 .

[10]  Karyotype Abnormalities.  DETECTION OF MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA , 2001 .

[11]  I. Lorand-Metze,et al.  The significance of trilineage myelodysplasia in de novo acute myeloblastic leukemia: clinical and laboratory features. , 1997, Haematologia.

[12]  W. Hiddemann,et al.  De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance. , 1996, Leukemia.

[13]  M. Tanimoto,et al.  Poor response to intensive chemotherapy in de novo acute myeloid leukaemia with trilineage myelodysplasia , 1994, British journal of haematology.

[14]  R. Gray,et al.  Prognostic importance of Sudan Black positivity: a study of bone marrow slides from 1386 patients with de novo acute myeloid leukaemia , 1991, British journal of haematology.

[15]  H. Schmetzer,et al.  Detection of minimal residual disease in acute myeloid leukemia. , 1990, Leukemia.

[16]  B. Clarkson,et al.  Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. , 1989, Blood.

[17]  M. Tomonaga,et al.  Dysmegakaryocytopoiesis in acute leukaemias: its predominance in myelomonocytic (M4) leukaemia and implication for poor response to chemotherapy , 1987, British journal of haematology.

[18]  D. Catovsky,et al.  Clinical and laboratory features of de novo acute myeloid leukaemia with trilineage myelodysplasia , 1987, British journal of haematology.

[19]  I Royston,et al.  Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia. , 1987, The New England journal of medicine.

[20]  J. Yunis,et al.  High-resolution chromosomes as an independent prognostic indicator in adult acute nonlymphocytic leukemia. , 1984, The New England journal of medicine.